Vildagliptin shows diabetes benefits but raises CV concerns

05/28/2013 | MedPage Today (free registration)

A study presented at the Heart Failure Congress found type 2 diabetes patients with heart failure who took vildagliptin attained lower HbA1C levels at 16 weeks compared with those in the placebo group. However, researchers noted higher rates of cardiovascular and all-cause mortality in vildagliptin-treated patients.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA